- Home
- FMY vs SER Comparison
FMY vs SER Comparison
Compare FMY & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- SER
- Stock Information
- Founded
- FMY 2005
- SER 2017
- Country
- FMY United States
- SER United States
- Employees
- FMY N/A
- SER N/A
- Industry
- FMY Finance/Investors Services
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- FMY Finance
- SER Health Care
- Exchange
- FMY Nasdaq
- SER Nasdaq
- Market Cap
- FMY 50.4M
- SER 45.2M
- IPO Year
- FMY N/A
- SER 2018
- Fundamental
- Price
- FMY $11.90
- SER $4.81
- Analyst Decision
- FMY
- SER
- Analyst Count
- FMY 0
- SER 0
- Target Price
- FMY N/A
- SER N/A
- AVG Volume (30 Days)
- FMY 10.1K
- SER 31.9K
- Earning Date
- FMY 01-01-0001
- SER 11-12-2024
- Dividend Yield
- FMY 6.98%
- SER N/A
- EPS Growth
- FMY N/A
- SER N/A
- EPS
- FMY N/A
- SER N/A
- Revenue
- FMY N/A
- SER $3,157,500.00
- Revenue This Year
- FMY N/A
- SER N/A
- Revenue Next Year
- FMY N/A
- SER N/A
- P/E Ratio
- FMY N/A
- SER N/A
- Revenue Growth
- FMY N/A
- SER 2454.55
- 52 Week Low
- FMY $10.71
- SER $3.81
- 52 Week High
- FMY $12.17
- SER $19.93
- Technical
- Relative Strength Index (RSI)
- FMY 48.60
- SER 46.26
- Support Level
- FMY $11.65
- SER $4.70
- Resistance Level
- FMY $11.78
- SER $5.40
- Average True Range (ATR)
- FMY 0.17
- SER 0.49
- MACD
- FMY 0.01
- SER -0.01
- Stochastic Oscillator
- FMY 55.56
- SER 11.93
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.